BioSpace News Archive

The SCOUT® Radar Breast Localization System was featured as the 2018 cutting edge technology for breast cancer patients as Good Morning America kicked off Breast Cancer Awareness Month. SCOUT, a non-radioactive, wire-free option for tumor and lymph node localization is available at over 350 hospitals across the United States and those numbers are growing.

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, congratulated Dr. James P. Allison, of the M.D. Anderson Cancer Center at the University of Texas, for his award as one of two recipients of the 2018 Nobel Prize in Medicine or Physiology for his pioneering work in immunotherapy that has transformed the way melanoma and many other cancers are now treated.

Spineology Inc., an innovator in anatomy-conserving spine surgery, is excited to announce that John Chi, M.D., M.P.H., Associate Professor of Neurosurgery at Harvard Medical School and the Director of Neurosurgical Spinal Oncology at Brigham and Women’s Hospital in Boston, Massachusetts, presented 12-month outcomes data from Spineology’s SCOUT clinical trial at the recent annual meeting of the North American Spine Society (NASS) in Los Angeles, California.

With 36 days left until the election, both candidates for California governor have committed to addressing the looming senior care crisis and creating a California master plan on aging.

CARLISLE today announces its partnership with National Breast Cancer Foundation, Inc.(R) (NBCF).

GW Pharmaceuticals plc announced today that it intends to sell, subject to market and other conditions, $300 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the Nasdaq Global Market in an underwritten U.S. public offering.

Ember Therapeutics, Inc. (OTCPK: EMBT, the “Company”), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that on October 1, 2018 the Company voluntarily filed a Form 15 with the United States Securities and Exchange Commission

ITI Founder & CEO will discuss new developments in cancer immunotherapy

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that new preclinical data from its TGFβ1 cancer immunotherapy program will be presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 9-11, 2018 at the Walter E. Washington Convention Center in Washington DC.

Physicians at the John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center have enrolled the first two patients nationwide in an international phase II clinical trial of Kazia Therapeutics’s novel therapy, GDC-0084, for glioblastoma.